EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced on March 4, 2024, the appointment of Dr. Ramiro Ribeiro as its new Chief Medical Officer, effective March 1, 2024. Dr. Ribeiro, a trained retinal specialist, succeeds Dr. Dario Paggiarino, who has served in the role since 2016 and will depart the company on March 31, 2024. Dr. Ribeiro's previous experience includes serving as Vice President, Head of Clinical Development at Apellis Pharmaceuticals, where he led the global Phase 3 clinical program in Geographic Atrophy. EyePoint Pharmaceuticals is preparing for the upcoming Phase 2 PAVIA trial results of EYP-1901 for NPDR in Q2 2024 and the initiation of the Phase 3 LUGANO trial in wet AMD in the second half of the year. The company's pipeline leverages its proprietary Durasert E™ technology for sustained intraocular drug delivery, with EYP-1901 being a leading product candidate. The announcement also included the grant of stock options to Dr. Ribeiro as an inducement award in accordance with Nasdaq Listing Rule 5635(c)(4).

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced on March 4, 2024, the appointment of Dr. Ramiro Ribeiro as its new Chief Medical Officer, effective March 1, 2024. Dr. Ribeiro, a trained retinal specialist, succeeds Dr. Dario Paggiarino, who has served in the role since 2016 and will depart the company on March 31, 2024. Dr. Ribeiro's previous experience includes serving as Vice President, Head of Clinical Development at Apellis Pharmaceuticals, where he led the global Phase 3 clinical program in Geographic Atrophy. EyePoint Pharmaceuticals is preparing for the upcoming Phase 2 PAVIA trial results of EYP-1901 for NPDR in Q2 2024 and the initiation of the Phase 3 LUGANO trial in wet AMD in the second half of the year. The company's pipeline leverages its proprietary Durasert E™ technology for sustained intraocular drug delivery, with EYP-1901 being a leading product candidate. The announcement also included the grant of stock options to Dr. Ribeiro as an inducement award in accordance with Nasdaq Listing Rule 5635(c)(4).